



## Annexin A5 and MFG-E8 as potential plasma biomarkers for Alzheimer's disease

Hitoshi Sohma

Hokkaido University, Japan

E-mail: [sohma@sapmed.ac.jp](mailto:sohma@sapmed.ac.jp)

Biomarker study on dementia has developed and the most reliable fluid markers are amyloid peptide ( $A\beta$ ), TAU, and phosphorylated TAU detected in cerebrospinal fluid. In addition, there is a great activity in blood-based markers of Alzheimer's disease (AD) because blood extraction is tons much less invasive. Moreover, plasma biomarkers can be measured at a tremendously low rate once a popular gadget of dimension is established. However, there is no longer yet an setup or validated diagnostic test for plasma biomarkers. Using a neuronal cell way of life mannequin we have observed that annexin A5 and Milkfat globule-EGF component eight protein (MFG-E8),  $Ca^{2+}$ , and phospholipid-binding proteins were expanded in the cell subculture medium via  $A\beta_{42}$  treatment. An immunohistochemical study the use of AD mouse mannequin (APPPS1) brains published attribute distributions of annexin A5 and MFG-E8: greater intensive staining with anti-annexin A5 antibody was located extensively in APPPS1 mice compared with control; whereas staining with anti-MFG-E8 antibody was once detected solely in the central phase of the anti- $A\beta$ -antibody stained plaque in APPPS1 mice, while no-staining was determined in control. As both annexin A5 and MFG-E8 might move the blood-brain barrier due to their lipid-binding property, it is potential that both proteins might be plasma biomarkers for AD. For measuring plasma degrees of them, we installed ELISA systems with monoclonal antibodies against annexin A5 and MFG-E8, respectively. The concentrations of both annexin A5 and MFG-E8 had been significantly greater in AD sufferers than in wholesome people ( $P < 0.0001$ ). From the ROC curve with plasma annexin A5 and MFG-E8 concentrations for the AD/control, the suggest areas underneath the curve were 0.898 and 0.723, respectively. Interestingly, the stage of plasma annexin A5 was also significantly greater in MCI sufferers than in manage ( $P < 0.0001$ ). This suggests that annexin A5 was multiplied at an early stage of AD. Alzheimer's ailment (AD) differs from different varieties of dementia in its relation to an amyloid beta-peptide (Abeta). Abeta, a proteolytic product of amyloid precursor proteins (APP), has a poisonous impact on neuronal cells, which involves perturbation of their  $Ca^{2+}$  homeostasis. This effect implies that modifications in protein expression in neuronal cells with calcium stress should furnish a molecular marker for this disease. In the current study, we used the supernatant from a neuronal cell way of life after incubation with or except Abeta and isolated a  $Ca^{2+}$ -dependent acidic phospholipid-binding fraction to function a proteomic study. Several unique proteins have been recognized after incubation with Abeta. We centered on annexin A5, amongst these proteins, because it binds each  $Ca^{2+}$  and lipids likely to be worried in calcium homeostasis. Tg2576 transgenic mice (AD model) overexpressing mutant human APP showed a full-size expansion of annexin A5 in the brain cortex however no longer in different organs, inclusive of liver, kidney, lung, and intestine. In human plasma samples, the stage of annexin A5 was extensively multiplied in a share of AD patients compared with a manage group ( $P < 0.0001$  in the logistic regression analysis). From the receiver operating characteristic (ROC) curve with plasma annexin A5 concentrations, the suggest region under the curve (AUC 0.898) suggests that annexin A5 is a favorable marker for AD. In Alzheimer's sickness (AD) amyloid- $\beta$  ( $A\beta$ ) deposits may additionally motive impairments in choroid plexus, a specialized brain shape that forms the blood-cerebrospinal fluid (CSF) barrier. We in the past carried out a mass proteomics-based learn about in choroid plexus from AD sufferers and we discovered several differentially regulated proteins compared with wholesome subjects. One of these proteins, annexin A5, was beforehand established implicated in blockading  $A\beta$ -induced cytotoxicity in neuronal mobile cultures. Here, we investigated the consequences of annexin A5 on  $A\beta$  toxicity in choroid plexus. We used choroid plexus tissue samples and CSF from moderate cognitive impairment (MCI) and AD sufferers to analyze  $A\beta$  accumulation, cell death, and annexin A5 tiers compared with manipulating subjects. Choroid plexus phone cultures from rats have been used to analyze annexin A5 outcomes on  $A\beta$ -induced cytotoxicity. AD choroid plexus exhibited a modern discount of annexin A5 levels along with gradually elevated  $A\beta$  accumulation and cell death as the sickness stage was higher. On the other hand, annexin A5 levels in CSF from sufferers had been observed gradually extended as the disorder stage multiplied in severity. In choroid plexus principal cultures,  $A\beta$  administration reduced endogenous annexin A5 levels in a time-course structured manner and simultaneously accelerated annexin A5 levels in the extracellular medium. Annexin A5 addition to choroid plexus cellphone cultures restored the  $A\beta$ -induced impairments on autophagy flux and apoptosis in a calcium-dependent manner. We suggest that annexin A5 would exert a protective function in choroid plexus and this safety is lost as  $A\beta$  accumulates with the disorder progression. Then, intelligence safety against further poisonous insults would be jeopardized.

**Bottom Note:** This work is partly presented at [International Conference on Biotechnology, Biomarkers & Systems Biology](#) March 04-05, 2019 | Amsterdam, Netherlands.